Geranylgeranyl diphosphate synthase (GGPPS) regulates non‐alcoholic fatty liver disease (NAFLD)–fibrosis progression by determining hepatic glucose/fatty acid preference under high‐fat diet conditions
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Patients with obesity have a high prevalence of non‐alcoholic fatty liver disease (NAFLD) and, in parallel, increased susceptibility to fibrosis/cirrhosis/hepatocellular carcinoma (HCC). Herein, we report that a high‐fat diet (HFD) can augment glycolysis and then accelerate NAFLD–fibrosis progression by downregulating the expression of geranylgeranyl diphosphate synthase (GGPPS), which is a critical enzyme in the mevalonate pathway. Long‐term HFD overloading decreases GGPPS expression in mice, which shifts the fuel preference from fatty acids towards glucose. Liver‐specific Ggpps deficiency drives the Warburg effect by impairing mitochondrial function, and then induces hepatic inflammation, thus exacerbating fibrosis. Ggpps deficiency also enhances the hyperfarnesylation of liver kinase B1, and promotes metabolic reprogramming by regulating 5′‐AMP‐activated protein kinase activity. Clinical data further imply that GGPPS expression can predict the stage of NAFLD and recurrence of NAFLD‐associated HCC. We conclude that the level of GGPPS is a susceptibility factor for NAFLD–fibrosis progression, and requires more stringent surveillance to ensure early prediction and precision of treatment of NAFLD‐related HCC. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“Although NAFLD patients without fibrosis may develop hepatocellular carcinoma (HCC), advanced fibrosis has been shown to increase the risk of HCC 25-fold [2,3].”
BackgroundDietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. (2015) · Nature · doi:10.1038/nature14232 · Cited by 2,055
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 1×
“Because LKB1 is a key upstream activator of AMPK, the LKB1–AMPK axis is a central metabolic switch in all eukaryotes regulating the balance between anabolism and catabolism [27].”
BackgroundPark, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 2×
“NAFLD-associated fibrosis is unclear, multiple studies have suggested that inflammation precedes the development of NAFLD, NASH and, subsequently, HCC [6,7].”
BackgroundSelective degradation of mitochondria by mitophagy
Kim, I., Rodriguez-Enriquez, S., & Lemasters, J. J. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.034 · Cited by 1,558
Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated Counterparts
Varum, S., Rodrigues, A. S., Moura, M. B., Momcilovic, O., Easley, C. A., Ramalho-Santos, J., Van Houten, B., & Schatten, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020914 · Cited by 671
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · cited 1×
“The patatin-like phospholipase domain containing 3 gene (Pnpla3) and TM6SF2 have been identified as potential regulators of the progression of NAFLD from steatosis to fibrosis and HCC [31,32].”
BackgroundTargeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Orchestration of Metabolism by Macrophages
Biswas, S. K., & Mantovani, A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.013 · Cited by 586 · cited 1×
“Glycolysis is essential for macrophage plasticity and polarization [28].”
BackgroundThoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523 · cited 1×
“Approaches used to treat risk factors associated with NAFLD include lifestyle interventions, medical treatments, and surgery [8,9].”
Background
Cited by
High fat diet, gut microbiome and gastrointestinal cancer
Tong, Y., Gao, H., Qi, Q., Liu, X., Li, J., Gao, J., Li, P., Wang, Y., Du, L., & Wang, C. (2021) · Theranostics · doi:10.7150/thno.56157 · Cited by 205
“Liu and colleagues found that long-term HFD can decrease the expression of geranylgeranyl diphosphate synthase in mice [31].”
BackgroundRisk assessment with gut microbiome and metabolite markers in NAFLD development
Leung, H., Long, X., Ni, Y., Qian, L., Nychas, E., Siliceo, S. L., Pohl, D., Hanhineva, K., Liu, Y., Xu, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abk0855 · Cited by 152
An update on animal models of liver fibrosis
Wu, S., Wang, X., Xing, W., Li, F., Liang, M., Li, K., He, Y., & Wang, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1160053 · Cited by 71
Targeting Small GTPases and Their Prenylation in Diabetes Mellitus
Gendaszewska-Darmach, E., Garstka, M. A., & Błażewska, K. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00410 · Cited by 35
Obesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20
Metadata
- Authors
- Liu, J., Jiang, S., Zhao, Y., Sun, Q., Zhang, J., Shen, D., Wu, J., Shen, N., Fu, X., Sun, X., Yu, D., Chen, J., He, J., Shi, T., Ding, Y., Fang, L., Xue, B., & Li, C.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2018-09-19
- Volume
- 246
- Issue
- 3
- Pages
- 277-288
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2811019994
- Cited by
- 72
- References
- 14
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Geranylgeranyl diphosphate synthase (GGPPS) regulates non‐alcoholic fatty liver disease (NAFLD)–fibrosis progression by determining hepatic glucose/fatty acid preference under high‐fat diet conditions. https://app.cochat.ai/papers/10.1002/path.5131
- The paper
- Liu, J., Jiang, S., Zhao, Y., Sun, Q., Zhang, J., Shen, D., Wu, J., Shen, N., Fu, X., Sun, X., Yu, D., Chen, J., He, J., Shi, T., Ding, Y., Fang, L., Xue, B., & Li, C. (2018). Geranylgeranyl diphosphate synthase (GGPPS) regulates non‐alcoholic fatty liver disease (NAFLD)–fibrosis progression by determining hepatic glucose/fatty acid preference under high‐fat diet conditions. The Journal of Pathology. https://doi.org/10.1002/path.5131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.